.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Clinicians managing heart failure now have a powerful tool for prognosis. The latest research indicates that FIND-AF risk stratification provides significant value for patients with heart failure with reduced ejection fraction (HFrEF). Many of these patients suffer from atrial cardiomyopathy (AtCM) even before developing atrial fibrillation (AF). This study evaluated a health records biomarker to predict critical clinical outcomes.
Researchers examined 164 patients from the ECG-HF registry between 2010 and 2016. They identified patients with HFrEF and AtCM but without baseline AF. The team used sex-specific thresholds to categorize patients into high and low-risk groups. Subsequently, they followed these individuals until the end of 2019 to track composite outcomes. Specifically, they monitored incident AF, ischaemic stroke, and all-cause mortality.
The results were striking for high-risk individuals. High-risk patients experienced a composite outcome rate of 71.9%. In contrast, only 50.8% of low-risk patients reached the same endpoint. Consequently, the findings suggest that the biomarker remains a strong independent predictor. Moreover, the model outperformed the traditional CHA2DS2-VASc score in terms of discrimination. Specifically, it showed significantly better accuracy for predicting ischaemic stroke and mortality.
However, this exploratory study requires further external validation. Despite this limitation, the data supports early risk assessment in HFrEF populations. Identifying high-risk patients allows for more vigilant monitoring. Furthermore, it might facilitate early interventions to prevent stroke. Thus, incorporating this biomarker into clinical workflows could improve patient management strategies significantly.
FIND-AF risk stratification identifies HFrEF patients at high risk for stroke and atrial fibrillation. This allows doctors to prioritize intensive monitoring for those without baseline AF.
Yes, this study demonstrated that FIND-AF offers superior discrimination (AUC 0.735) compared to CHA2DS2-VASc (AUC 0.641) for composite outcomes and ischaemic stroke.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Hsu JC et al. Stratifying prognosis in heart failure patients with reduced ejection fraction and atrial cardiomyopathy. ESC Heart Fail. 2026 May 21. doi: undefined. PMID: 42168766.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
High FIND-AF risk predicts adverse outcomes in HFrEF patients with atrial cardiomyopathy, outperforming CHA2DS2-VASc in stroke and mortality prediction....
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
